Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$550.72 USD

550.72
457,169

+3.25 (0.59%)

Updated Aug 27, 2024 04:00 PM ET

After-Market: $551.01 +0.29 (0.05%) 5:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (170 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Is McKesson Corporation (MCK) a Great Stock for Value Investors?

Is McKesson Corporation (MCK) a great pick from the value investor's perspective right now? Read on to know more.

Cardinal Health Strong on Pharmaceutical, Competition Rife

Cardinal Health (CAH) is on track to deliver targeted annualized cost savings of $100 million in fiscal 2019.

Here's Why You Should Invest in McKesson (MCK) Stock Now

McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.

MCK vs. ALGN: Which Stock Should Value Investors Buy Now?

MCK vs. ALGN: Which Stock Is the Better Value Option?

Are Investors Undervaluing McKesson (MCK) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

McKesson (MCK) Beats on Q3 Earnings, Gains From Solid View

McKesson (MCK) gains from the U.S. Pharmaceutical and Specialty Solutions segment in third-quarter fiscal 2019.

McKesson (MCK) Q3 Earnings and Revenues Beat Estimates

McKesson (MCK) delivered earnings and revenue surprises of 6.92% and 1.69%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Medical Products' Earnings Lineup for Jan 31: EW, BAX & More

Let's take a look at the factors that are likely to influence the earnings results of a few Medical Products bigwigs within the broader Medical space.

Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?

McKesson (MCK) expects to gain from solid segmental performances in third-quarter fiscal 2019.

Earnings Preview: McKesson (MCK) Q3 Earnings Expected to Decline

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Investors Should Hold McKesson (MCK) Stock Now

McKesson (MCK) gains traction from a solid foothold in the pharmaceutical and medical supplies distribution market. However, the company is grappled with regulatory constraints in Canada.

Genpact (G) Extends Multiyear Relationship With McKesson

The relationship is based on a combination of Genpact's deep operations optimization experience and McKesson's operational excellence.

Here's Why You Should Hold on to Cerner (CERN) Stock for Now

A bullish guidance for 2018 and a series of latest developments make Cerner (CERN) a promising investment pick.

Cerner (CERN) Collaborates With McKesson's CoverMyMeds

Cerner's (CERN) ePrescribe workflow solution is likely to partner with CoverMyMeds' RxBenefit Clarity solution for prescription price transparency.

Is McKesson (MCK) a Great Stock for Value Investors?

Let???s see if McKesson (MCK) stock is a good choice for value-oriented investors right now from multiple angles.

Rite Aid (RAD) Stock Up on Q3 Earnings Beat, FY19 View Down

Rite Aid's (RAD) top and bottom lines improve year over year. Also, earnings came ahead of the Zacks Consensus Estimate but sales lagged the same.

Is McKesson (MCK) a Suitable Stock for Value Investors Now?

Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

BD Brings HealthSight Diversion App to Combat Opioid Crisis

BD's (BDX) latest development is likely to boost the company's Medication Management unit.

McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates

McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.

McKesson (MCK) Surpasses Q2 Earnings Estimates

McKesson (MCK) delivered earnings and revenue surprises of 9.76% and -0.90%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Medical Product Earnings Lineup for Oct 25: SYK, CERN & More

Long-term potential of the Medical Products industry looks promising at the moment amid certain short-term geopolitical insecurities.

Can Diagnostic Revenues Drive PerkinElmer (PKI) Q3 Earnings?

PerkinElmer (PKI) likely to gain from strong segmental revenues in Q3; a raised earnings guidance for 2018 is promising.

Can Medication Delivery Unit Aid Baxter's (BAX) Q3 Earnings?

Baxter (BAX) likely to gain from strong Medication Delivery revenues; guidance for 2018 raised.

Will Core MedSurg Segment Aid Stryker's (SYK) Q3 Earnings?

Stryker (SYK) is likely to gain from strong segmental performance in Q3; softness anticipated in Spine business.

Will Core Business Units Aid McKesson's (MCK) Q2 Earnings?

McKesson (MCK) is expected to gain from strong segmental performances in Q2 of fiscal 2019.